Clinical Trial Update: Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating nivolumab and dasatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Northwestern University | Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2020-01-31